Navigation Links
InCube Labs Enters into an Agreement with the Engineering Research Center for Revolutionizing Metallic Biomaterials
Date:10/23/2013

SAN JOSE, Calif., Oct. 23, 2013 /PRNewswire/ -- InCube Labs, a life sciences research lab focused on developing and commercializing medical breakthroughs, today announced it has entered into an agreement with the Engineering Research Center for Revolutionizing Metallic Biomaterials (ERC-RMB). 

The ERC-RMB is funded by the National Science Foundation and led by North Carolina Agricultural and Technical State University in Greensboro (N.C. A&T) in collaboration with the University of Pittsburgh (Pitt), the University of Cincinnati, and Hannover Medical School in Germany. Its mission is to develop and commercialize novel bioresorbable metal alloys that have potential applications in implantable medical devices.  As part of this collaboration, InCube Labs has entered into an agreement to evaluate potential clinical utility of the novel biomaterials being developed at the ERC-RMB.

"The mission of the ERC-RMB is to create next-generation, revolutionary biological metallic interface materials for engineered systems implanted in the human body. Our team of innovative engineers has made strong progress in advancing our bioresorbable metals technologies, and we have been testing their use in clinically relevant device prototypes," said Dr. Jag Sankar, ERC Director and Distinguished Professor of Mechanical Engineering at N.C. A&T. 

Sankar continued, "Our next step now is to work with industry to bring these innovations to market and to patients. InCube Labs has a tremendous track record of success in developing and commercializing breakthrough technologies, and we are thrilled with this relationship with InCube to advance our novel biomaterials to the next phase of development." 

"The University of Pittsburgh is deeply committed to bridging the gap between academia and industry to promote and commercialize ne
'/>"/>

SOURCE InCube Labs
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. InCube Labs Launches Two New Life Sciences Companies in San Antonio
2. Lung Cancer Alliance Congratulates 75 Medical Centers For Moving Swiftly And Responsibly On Lung Cancer Screening
3. Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis
4. CyberKnife System and the da Vinci Surgical System in Concord Medical Centers Achieve Over RMB 10 Million in Medical Revenue Since Opening in February
5. 3 Pediatric Centers that Offer SynCardia Total Artificial Heart Named in Top 10 for "Best Childrens Hospitals"
6. Abaxis Enters Into Definitive Agreement To Deliver 300 Piccolo Xpress Instruments For A Four-Year Drug Clinical Trial
7. The Galien Foundation Announces Roster of Luminary Presenters for Third Galien Forum; Program Highlights Include CEO Panel, Panel on Alzheimers Disease Innovation, Nobel Laureate Elie Wiesel
8. ApolloMed ACO Selected To Participate In A Transformative New Initiative Sponsored by the Centers for Medicare and Medicaid Services
9. Spine Pain Management Opens Two Additional Affiliate Diagnostic Centers in Florida
10. Caspase Inhibitor Enters Clinical Trial In Islet Transplantation As Treatment For Diabetes
11. CVS Caremark Charitable Trust Partners with National Association of Community Health Centers to Create Innovative Grant Program Focused on Managing Chronic Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 2015 Celtaxsys, Inc., a clinical stage pharmaceutical ... rare and orphan inflammatory disease indications, announced today that ... Drug Administration (FDA) to begin a Phase 2 clinical ... adult CF patients in the US. The regulatory submissions ... will be filed soon after. This groundbreaking clinical ...
(Date:7/6/2015)... SOUTH SAN FRANCISCO, Calif. , July 6, 2015 ... leading global pharmaceutical company, and Oculeve, a development-stage medical ... eye disease, today announced that they have entered into ... an all-cash transaction.  Under the terms of the agreement, ... payment and commercialization milestone payments related to Oculeve,s lead ...
(Date:7/6/2015)... SHENZHEN, China , July 6, 2015 China ... CNIT), a leading provider of integrated cloud-based platform, exchange, ... , today announced that the Company launched its mobile ... age of accessible healthcare services on mobile devices. The ... District Health and Family Planning Bureau and Shenzhen News ...
Breaking Medicine Technology:Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 2Allergan to Acquire Oculeve Dry Eye Disease Development Programs 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 4CNIT Launches the Mobile App for Healthcare One Pass 2CNIT Launches the Mobile App for Healthcare One Pass 3CNIT Launches the Mobile App for Healthcare One Pass 4
... 8 Cell Therapeutics, Inc. (CTI),(Nasdaq and ... data for the,Zevalin(R) ([90Y]-ibritumomab tiuxetan) First-line Indolent ... Hematology (ASH) 50th Annual Meeting by,Morschhauser, et ... (PFS) following Zevalin consolidation therapy for patients ...
... Patients with non-valvular,atrial fibrillation receiving either 30 mg ... oral Factor Xa inhibitor, experienced comparable,safety and tolerability ... II data presented today at the 50th Annual ... Francisco. These findings are the first results,from ...
Cached Medicine Technology:Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 2Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 3Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 4Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 5New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation 2New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation 3New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation 4New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation 5
(Date:7/7/2015)... ... July 07, 2015 , ... Nationally-renowned attorneys in the realm ... the Invokana Ketoacidosis Lawsuit Center . The website provides information on Invokana ... persons wishing to learn more about Invokana lawsuits for kidney problems, ketoacidosis, heart ...
(Date:7/7/2015)... ... July 07, 2015 , ... Clarion Safety Systems , ... featured in the latest issue of In Compliance Magazine, a leading source for ... delivers the latest news, standards updates, technical explanations and guidance, as a resource ...
(Date:7/7/2015)... Washington, DC (PRWEB) , ... July 07, 2015 ... ... Operating Officer and well-known patient advocate, will be recognized by the White House ... , Part of the newly-launched President’s Precision Medicine Initiative, the Champions of Change ...
(Date:7/7/2015)... ... July 07, 2015 , ... Each year the Holiday Inn ... on a local, national and international level; however, the Holiday Inn now hosts one ... a high impact on the beneficiaries. In September of 2014 they hosted an event ...
(Date:7/6/2015)... London, UK (PRWEB) , ... July 07, 2015 ... ... segments in the in vitro universe. Increasing incidence of AIDS, advances in the ... the key growth driving forces. Recent advances in detection technologies and genetic engineering ...
Breaking Medicine News(10 mins):Health News:National Attorneys Launch Invokana Ketoacidosis Lawsuit Center 2Health News:National Attorneys Launch Invokana Ketoacidosis Lawsuit Center 3Health News:Standards Considerations for Laser Safety Labels from Clarion Safety Systems Featured in In Compliance Magazine 2Health News:Standards Considerations for Laser Safety Labels from Clarion Safety Systems Featured in In Compliance Magazine 3Health News:Standards Considerations for Laser Safety Labels from Clarion Safety Systems Featured in In Compliance Magazine 4Health News:White House names Champions of Change for Precision Medicine: CareSync COO Recognized 2Health News:White House names Champions of Change for Precision Medicine: CareSync COO Recognized 3Health News:The Holiday Inn Westbury - Long Island Will Host a Fundraising Event on September 16th 2015 from 6:00 pm - 10:00 pm to Benefit Angela's House located on Long Island 2Health News:The Holiday Inn Westbury - Long Island Will Host a Fundraising Event on September 16th 2015 from 6:00 pm - 10:00 pm to Benefit Angela's House located on Long Island 3Health News:World Infectious Disease Testing Market Examined by VPGMarketResearch.com in In-Demand Report Available at MarketPublishers.com 2Health News:World Infectious Disease Testing Market Examined by VPGMarketResearch.com in In-Demand Report Available at MarketPublishers.com 3
... to exercise within 6 months , , MONDAY, March 30 ... their own stem cells into the heart muscle appears ... say U.S. researchers. , "The results from this study ... cells could actually be used as a treatment for ...
... March 30 TrinityCare Senior Living, Inc. (OTC ... faith-based senior living facilities, today announced that it ... and implement a comprehensive investor relations program for ... investment research and financial communications firm that seeks ...
... PharmAthene, Inc. (NYSE Amex: PIP ), ... chemical threats, today reported operational and financial results for ... ended December 31, 2008 and 2007, the Company reported ... Revenues for the full year 2008 consisted primarily of ...
... published in the March/April issue of the journal Nursing ... nurses from leaving their jobs and in doing so ... another position or retire early, it dramatically affects a hospital,s ... hospital,s budget may go to paying for nursing turnover costs. ...
... CLEVELAND, March 30 Inajo Davis Chappell, Partner ... Resources as the first recipient of the Helen K. Jones ... of understanding the nuances and complexities of the non-profit arena, ... over many years. In addition to a stellar career ...
... Bausch & Lomb has announced a partnership in the U.S., ... that helps individuals identify their perfect style type. The firm ... life for women and men through the " See a ... Bausch & Lomb at: http://inr.mediaseed.tv/Bausch_Lomb_36321 ...
Cached Medicine News:Health News:Stem Cell Injections Seem to Reduce Angina Pain 2Health News:TrinityCare Senior Living, Inc. Retains RJ Falkner & Company, Inc. as Investor Relations Counsel 2Health News:TrinityCare Senior Living, Inc. Retains RJ Falkner & Company, Inc. as Investor Relations Counsel 3Health News:PharmAthene Reports Year End 2008 Financial Results 2Health News:PharmAthene Reports Year End 2008 Financial Results 3Health News:PharmAthene Reports Year End 2008 Financial Results 4Health News:PharmAthene Reports Year End 2008 Financial Results 5Health News:PharmAthene Reports Year End 2008 Financial Results 6Health News:PharmAthene Reports Year End 2008 Financial Results 7Health News:Keeping nurses on the job: Retention is part of the answer to the nursing shortage 2Health News:Recovery Resources to Honor Ulmer & Berne Attorney Inajo Davis Chappell with the Helen K. Jones Woman of Strength Memorial Award 2Health News:VIDEO from Medialink and Bausch & Lomb: Bausch & Lomb Partners With Visual Therapy to Help Women Nationwide 'See a New You' 2
... white LED (Light Emitting Diode) light source, coupled ... the freedom of using a slit lamp anywhere ... about 1.5 lbs. (0.68 kg) with its battery ... Its ergonomic, portable design and convenient carrying ...
Powerful LED Illumination , The ultrabright and compact 3S LED HeadLight from HEINE for Powerful, coaxial illumination...
... Abnormal Control Serum is intended for monitoring the ... assays. It is for in vitro diagnostic use ... format, the control offers up to ten days ... control is to be used in accordance with ...
e-MDs Bill practice management system is used in the medical billing cycle....
Medicine Products: